World's Best Scientists 2026 revealed!
José M. Gatell

José M. Gatell

Award Badge
Microbiology
Spain
2026

D-Index & Metrics

Microbiology

D-Index
98
Citations
41092
World Ranking
451
National Ranking
9

Medicine

D-Index
98
Citations
42661
World Ranking
8826
National Ranking
126

Research.com Recognitions

  • 2026 - Research.com Microbiology in Spain Leader Award
  • 2025 - Research.com Microbiology in Spain Leader Award

Overview

José M. Gatell is affiliated with the University of Barcelona in Spain. Their research primarily focuses on fields within medicine, particularly immunology and microbiology, with a significant emphasis on infectious diseases. They have contributed extensively to the study of HIV/AIDS, including drug development, treatment, and related health complications.

Their research topics include:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV/AIDS Research and Interventions
  • Pharmacological Effects and Toxicity Studies
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Immune Cell Function and Interaction

José M. Gatell has published papers across a variety of journals and venues. Frequent publication venues include:

  • UNC Libraries
  • Journal of Antimicrobial Chemotherapy
  • The Lancet HIV
  • Clinical Infectious Diseases
  • AIDS Research and Human Retroviruses

Notable recent papers authored or co-authored by José M. Gatell include:

  • Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society-USA Panel, 2020, UNC Libraries
  • Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial, 2021, The Lancet HIV
  • Immunological and virological findings in a patient with exceptional post-treatment control: a case report, 2022, The Lancet HIV
  • Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial, 2023, Clinical Infectious Diseases
  • Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease, 2020, Journal of Antimicrobial Chemotherapy

Throughout their career, José M. Gatell has frequently collaborated with several co-authors. These include:

  • Peré Domingo
  • Bonaventura Clotet
  • Estebán Martínez
  • Christoph Stephan
  • Elisa de Lazzari

Their work spans numerous subfields in medicine such as infectious diseases, virology, emergency medicine, pediatrics, perinatology and child health, and epidemiology, reflecting a broad scope of study within clinical and therapeutic contexts.

Best Publications

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

    Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  • Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation.

    A Torres;J M Gatell;E Aznar;M el-Ebiary

  • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Maria J Buzón;Marta Massanella;Josep M Llibre;Anna Esteve

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

    Sean Emery;Jacqueline A. Neuhaus;Andrew N. Phillips;Abdel Babiker

  • Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

    Esteban Martínez;Amanda Mocroft;Miguel A García-Viejo;José B Pérez-Cuevas

  • Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.

    Amanda Mocroft;Ole Kirk;Peter Reiss;Stephane De Wit

  • Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

    François Raffi;Hans Jaeger;Eugenia Quiros-Roldan;Helmut Albrecht

  • Beyond viral suppression of HIV – the new quality of life frontier

    Jeffrey V. Lazarus;Jeffrey V. Lazarus;Kelly Safreed-Harmon;Simon E. Barton;Dominique Costagliola

  • Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

    Esteban Martinez;José L. Blanco;Juan A. Arnaiz;José B. Perez-Cuevas

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

    Kathleen Squires;Adriano Lazzarin;José M. Gatell;William G. Powderly

  • Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

    Esteban Martínez;Juan A. Arnaiz;Daniel Podzamczer;David Dalmau

  • Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama

Frequent Co-Authors

Felipe García
Felipe García University of Barcelona
José M. Miró
José M. Miró University of Barcelona
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Josep Mallolas
Josep Mallolas University of Barcelona
Tomás Pumarola
Tomás Pumarola Vall d'Hebron Institut de Recerca
Amanda Mocroft
Amanda Mocroft University College London
Pere Domingo
Pere Domingo Autonomous University of Barcelona
Peter Reiss
Peter Reiss University of Amsterdam
Andrew N. Phillips
Andrew N. Phillips University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to microbiology can open doors to diverse career paths in health and science fields. For instance, becoming a certified child life specialist offers rewarding opportunities supporting children through medical experiences. Understanding a certified child life specialist salary can help students gauge the financial benefits alongside their passion for care.

Many students face unique challenges when pursuing education, including those with legal histories. Fortunately, several degrees felons can get provide a pathway to meaningful careers, demonstrating that academic advancement remains accessible and achievable.

The healthcare sector also offers specialized roles like the functional medicine nurse practitioner, blending traditional and holistic practices. Learning about the functional medicine nurse salary helps prospective students assess financial prospects in this growing field.

For those interested in medical administration, pursuing certification as a professional coder is another viable career route. Information regarding the certified professional coder salary highlights earning potential and job stability within healthcare coding and billing.

Best Scientists Citing José M. Gatell

Trending Scientists

Recently Published Articles